Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Genelux Corp., retaining the price target of $31.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emily Bodnar’s rating is based on the promising clinical data and potential of Genelux Corp.’s Olvi-Vec treatment. The preliminary results from the Phase 1b/2 dose-escalation trial for small cell lung cancer (SCLC) in China have shown a high disease control rate and partial responses, which are significant compared to existing second-line treatments. The data suggest that Olvi-Vec, when combined with platinum chemotherapy, could offer a differentiated efficacy profile, especially given the historical low response rates of other treatments.
Furthermore, the ongoing trials and planned dose escalations indicate a potential for even better outcomes with higher doses. The company’s strategy to explore intravenous administration of Olvi-Vec, which has previously been used intraperitoneally, opens up possibilities for its application across various solid tumors. These factors collectively contribute to the Buy rating, as they highlight the potential for Olvi-Vec to become a significant player in the oncology treatment landscape.
Bodnar covers the Healthcare sector, focusing on stocks such as Arcellx Inc, Agenus, and NovoCure. According to TipRanks, Bodnar has an average return of -2.5% and a 30.33% success rate on recommended stocks.